Estimated at USD 67.50 billion in 2025, the Blood Cancer Drugs Market is projected to grow from USD 74.44 billion in 2026 to USD 164.04 billion by 2034, registering a CAGR of 10.4% during 2026–2034. North America dominated in 2025. Rising incidence of hematological malignancies and longer treatment durations drive demand. Leukemia targeted therapies held the largest indication share...